ImmunoGen, Inc. (IMGN) Q1 2022 Results Conference Call May 6, 2022 8:00 AM ET
Company Participants
Courtney O'Konek - Senior Director, Corporate Communications
Mark Enyedy - President, CEO
Anna Berkenblit - CMO
Kristen Harrington-Smith - Chief Commercial Officer
Susan Altschuller - CFO
Conference Call Participants
Boris Peaker - Cowen
Kelly Shi - Jefferies
Etzer Darout - BMO Capital Markets
Jessica Fye - JPMorgan
John Newman - Canaccord
Joe Catanzaro - Piper Sandler
Michael Schmidt - Guggenheim
Andy Hsieh - William Blair
Jonathan Chang - SVB Securities
Operator
Good morning and welcome to ImmunoGen's First Quarter 2022 Financial and Operating Results Conference Call. Today's conference is being recorded.
At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications. Please go ahead.
Courtney O'Konek
Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent progress and first quarter 2022 financial results. This press release and a recording of this call can be found under the Investors & Media section of our website at immunogen.com.
With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; Kristen Harrington-Smith, our Chief Commercial Officer; and Susan Altschuller, our CFO. During today's call, we will review recent accomplishments for the business, our Q1 financial results and highlight upcoming anticipated events.
We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties, and our actual results may differ materially, please consult the risks outlined in our press release issued this morning in the Risk Factors section of our most recent annual report on Form 10-K and in our other SEC filings, which are available at sec.gov and immunogen.com.
And with that, I'll
- Read more current IMGN analysis and news
- View all earnings call transcripts